Literature DB >> 19669254

Effect of natural interferon α on proliferation and apoptosis of hepatic stellate cells.

Tomohiro Ogawa, Norifumi Kawada, Kazuo Ikeda.   

Abstract

Inhibition of the proliferation of hepatic stellate cells (HSC) is clinically important for the control of liver fibrosis and cirrhosis. Interferons are now frequently used for chronic viral hepatitis because of their anti-viral activity. However, patients treated with interferons exhibit a regression of liver fibrosis even if viral eradication is not achieved, indicating that interferon itself has anti-fibrotic activity. Herein, we show the anti-proliferation and pro-apoptotic activity of natural interferon α against HSC. We found that interferon α inhibited serum-stimulated [(3)H]thymidine incorporation of HSC in a dose-dependent manner, with a significant reduction at more than 100 U/ml. Interferon α also attenuated PDGF-BB-stimulated DNA synthesis of HSC. Although the molecular mechanism behind these phenomena has not been defined, we found that interferon α triggers the apoptosis of HSC treated with low-dose tumor necrosis factor α, as determined by the Alamar blue assay, morphology, and DNA ladder formation. Furthermore, interferon α decreased inhibitor of caspase-activated DNase (ICAD) levels, which may augment tumor necrosis factor α-induced cell death signals. Thus, interferon α regulates the number of myofibroblastic hepatic stellate cells and may clinically contribute to the regression of human liver fibrosis.

Entities:  

Year:  2009        PMID: 19669254      PMCID: PMC2748375          DOI: 10.1007/s12072-009-9129-y

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  31 in total

Review 1.  Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury.

Authors:  S L Friedman
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

Review 2.  Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex.

Authors:  F J Eng; S L Friedman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-07       Impact factor: 4.052

3.  Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells.

Authors:  N Kawada; S Seki; M Inoue; T Kuroki
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

4.  Interferon gamma treatment prevents procollagen gene expression without affecting transforming growth factor-beta1 expression in pig serum-induced rat liver fibrosis in vivo.

Authors:  I Sakaida; K Uchida; Y Matsumura; K Okita
Journal:  J Hepatol       Date:  1998-03       Impact factor: 25.083

5.  Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.

Authors:  Y Shiratori; F Imazeki; M Moriyama; M Yano; Y Arakawa; O Yokosuka; T Kuroki; S Nishiguchi; M Sata; G Yamada; S Fujiyama; H Yoshida; M Omata
Journal:  Ann Intern Med       Date:  2000-04-04       Impact factor: 25.391

6.  Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis.

Authors:  G S Baroni; L D'Ambrosio; P Curto; A Casini; R Mancini; A M Jezequel; A Benedetti
Journal:  Hepatology       Date:  1996-05       Impact factor: 17.425

7.  Transforming growth factor beta and tumor necrosis factor alpha inhibit both apoptosis and proliferation of activated rat hepatic stellate cells.

Authors:  B Saile; N Matthes; T Knittel; G Ramadori
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

8.  Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture.

Authors:  A Mallat; A M Preaux; S Blazejewski; J Rosenbaum; D Dhumeaux; P Mavier
Journal:  Hepatology       Date:  1995-04       Impact factor: 17.425

9.  Collagen synthesis by human liver (myo)fibroblasts in culture: evidence for a regulatory role of IL-1 beta, IL-4, TGF beta and IFN gamma.

Authors:  A M Tiggelman; W Boers; C Linthorst; M Sala; R A Chamuleau
Journal:  J Hepatol       Date:  1995-09       Impact factor: 25.083

10.  Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma.

Authors:  D C Rockey; J J Maher; W R Jarnagin; G Gabbiani; S L Friedman
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

View more
  6 in total

Review 1.  Delivery and targeting of miRNAs for treating liver fibrosis.

Authors:  Virender Kumar; Ram I Mahato
Journal:  Pharm Res       Date:  2014-09-04       Impact factor: 4.200

2.  Targeting N-acetylglucosamine-bearing polymer-coated liposomes to vascular smooth muscle cells.

Authors:  Mamiko Ise; Hirohiko Ise; Yuji Shiba; Satoshi Kobayashi; Mitsuaki Goto; Masafumi Takahashi; Toshihiro Akaike; Uichi Ikeda
Journal:  J Artif Organs       Date:  2011-08-02       Impact factor: 1.731

Review 3.  Pathogenesis of liver cirrhosis.

Authors:  Wen-Ce Zhou; Quan-Bao Zhang; Liang Qiao
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

4.  Genetic resistance to liver fibrosis on A/J mouse chromosome 17.

Authors:  David A DeSantis; Peter Lee; Stephanie K Doerner; Chih-Wei Ko; Jean H Kawasoe; Annie E Hill-Baskin; Sheila R Ernest; Prerna Bhargava; Kyu Yeon Hur; Gail A Cresci; Michele T Pritchard; Chih-Hao Lee; Laura E Nagy; Joseph H Nadeau; Colleen M Croniger
Journal:  Alcohol Clin Exp Res       Date:  2013-06-13       Impact factor: 3.455

Review 5.  Hepatic Stellate Cells and microRNAs in Pathogenesis of Liver Fibrosis.

Authors:  Mio Kitano; P Mark Bloomston
Journal:  J Clin Med       Date:  2016-03-16       Impact factor: 4.241

6.  Geranylgeranylacetone attenuates fibrogenic activity and induces apoptosis in cultured human hepatic stellate cells and reduces liver fibrosis in carbon tetrachloride-treated mice.

Authors:  Takemasa Senoo; Ryu Sasaki; Yuko Akazawa; Tatsuki Ichikawa; Satoshi Miuma; Hisamitsu Miyaaki; Naota Taura; Kazuhiko Nakao
Journal:  BMC Gastroenterol       Date:  2018-02-27       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.